Warner-Lambert Company

Other

Daniel Fred Ortwine

Andrew David White

Claude Forsey Purchase, Jr

Patrick Michael O'Brien

David T Connor

William Chester Patt

Michael William Wilson

Nicole Chantel Barvian

Drago R Sliskovic

John Michael Domagala

Joseph Armand Picard

Graham Johnson

Gordon William Rewcastle

Christopher Franklin Bigge

Edmund Lee Ellsworth

Edward Faith Elslager

Bradley Dean Tait

Elizabeth Ann Lunney

Howard D Showalter

Leslie M Werbel

John Quin, Iii

Linda Lea Johnson

Anthony Denver Sercel

Sheryl Jeanne Hays

Julie Ann Spicer

Mark Stephen Plummer

Donald John Hupe

Michael David Kaufman

Tomi Sawyer

David B Capps

Qi-Zhuang Ye

Kimberly Suzanne Para

Kevon Ray Shuler

Donald F Worth

Aurash B Shahripour

Josyula Venkata Prasad

Vlad E Gregor

Ellen M Berman

Perry M Novak

Shannon Leigh Black

Christopher Alan Conrad

Christopher Emil Whitehead

The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives

Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,wherein:

Pyridine matrix metalloproteinase inhibitors

This invention provides compounds defined by Formula Ior a pharmaceutically acceptable salt thereof,wherein R, Q, Y, Y, Y, U, U, U, and Rare as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

Chromone derivatives as matrix metalloproteinase inhibitors

Selective MMP-13 inhibitors are pyridine derivatives of the formulaor a pharmaceutically acceptable salt thereof,

Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors

Sulfonamide compounds are described which are inhibitors of matrix metalloproteinases, particularly stromelysin-1 and gelatinase A (72 kD gelatinase). Also described are methods for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes using the compounds.

Sulfonamide inhibitors of matrix metalloproteinases

Aromatic keto-acids and their derivatives as inhibitors of matrix

The present invention relates to novel tri- and tetrasubstituted pyrones and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The pyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized pyrones and of related structures.

Pyrone derivatives as protease inhibitors and antiviral agents

A novel series of polycyclic amines, derivatives, methods of making the compounds, novel intermediates, compositions containing them, and methods for using them in the treatment and prevention of cerebrovascular disorders are disclosed.

Polycyclic amines useful as cerebrovascular agents

Substituted 2H-[1]benzopyrano[4,3,2-cd]indazoles, 2H-[1]benzothiopyrano[4,3,2-cd]indazoles, and 2H-[1]benzoselenino[4,3,2-cd]indazoles have demonstrated pharmacological activity against a broad spectrum of Gram-positive and Gram-negative bacteria, yeasts, and fungi, as well as activity against the L1210 and P388 murine leukemia cells lines. Pharmaceutical compositions containing the compounds and methods of employing the compounds in methods of treating bacterial or fungal infections and of inhibiting the growth of neoplasms in mammals are also disclosed.

Antibacterial benzo(chalcogeno)[4,3,2-cd]indazoles

Growing community of inventors

Saline, MI, United States of America

Daniel Fred Ortwine